305MO SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

Y. Yu, N. Yang,Y. Zhang,H. Zhang,M. Li, Q. Yu,J. Zhou,X. Hu, J. Fang, H. Zhao,J. Feng,L. Li, Y. Shu,X. Wang, M. Sun,J. Zhang,M. Li, Y. Ren,S. Lu

Annals of Oncology(2022)

引用 0|浏览9
暂无评分
摘要
MET Amplification (METamp) commonly mediates resistance to EGFR TKIs in NSCLC patients with EGFR-mutation. Several clinical trials showed that the combination of MET inhibition with EGFR TKI is a promising therapeutic strategy to overcome the MET amplification-mediated resistance. SCC244 is a highly selective small molecular inhibitor of MET kinase. It was well tolerated and has shown favorable anti-tumor activities in patients with MET aberration as monotherapy in clinical studies.
更多
查看译文
关键词
egfr tki,osimertinib,egfr-mutant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要